Nanoparticle delivery to tumours: from EPR and ATR mechanisms to clinical impact

Dasgupta, Anshuman; Sofias, Alexandros Marios; Kiessling, Fabian; Lammers, Twan

doi:10.1038/s44222-024-00203-3

Nat Rev Bioeng

2024

DOI: 10.1038/s44222-024-00203-3

|View full text |Cite

Nanoparticle delivery to tumours: from EPR and ATR mechanisms to clinical impact

Anshuman Dasgupta,

Alexandros Marios Sofias,

Fabian Kiessling

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Recent Advances in Pretargeted Strategy for Cancer Theranostics

Tian,

Huang,

Luo

et al. 2024

ChemMedChem

View full text Add to dashboard Cite

In nuclear medicine, theranostic probes that combine nuclear imaging capabilities with therapeutic functions have shown promise for the diagnosis and treatment of cancers. Nevertheless, the development of theranostic probes may be constrained by two principal factors: (1) the discrepancy between the slow accumulation time of the probes in the tumours and the short‐lived radionuclides, and (2) the suboptimal imaging/treatment effect and high radioactive toxicity caused by long‐lived radionuclides. In recent years, pretargeted strategy has been proposed as a potential solution to solve these problems. In the pretargeted strategy, two components consisting of a tumour‐targeting vector (e.g., antibody) and a radionuclide are injected separately, which can then couple in the tumour tissues to trap radionuclides for nuclear imaging and/or therapy. This two‐step process allows for the independent optimization of the pharmacokinetics of them in vivo, benefiting to improve nuclear imaging and/or therapy of tumours in vivo. In this concept, we will discuss the principle of the pretargeted strategy, with a focus on the discussion of different tumour‐targeting vectors, including antibody‐mediated delivery, nanoparticle‐mediated delivery, metabolic glycan labeling‐mediated accumulation, and enzyme‐triggered in situ self‐assembly‐mediated retention. Finally, we will discuss the current challenges and perspectives on their applications for cancer theranostics in clinics.

show abstract

Recent Advances in Pretargeted Strategy for Cancer Theranostics

Tian,

Huang,

Luo

et al. 2024

ChemMedChem

View full text Add to dashboard Cite

show abstract

Polyphenol encapsulated nanofibers in wound healing and drug delivery

Ejiohuo,

Folami,

Edi

et al. 2024

European Journal of Medicinal Chemistry Reports

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Nanoparticle delivery to tumours: from EPR and ATR mechanisms to clinical impact

Cited by 2 publications

References 9 publications

Recent Advances in Pretargeted Strategy for Cancer Theranostics

Recent Advances in Pretargeted Strategy for Cancer Theranostics

Polyphenol encapsulated nanofibers in wound healing and drug delivery

Contact Info

Product

Resources

About